Abstract: Pregnant and lactating women have historically been excluded from clinical trials, limiting data on drug pharmacokinetics, safety, and efficacy in these populations. Recent legislative frameworks have catalyzed efforts to include these populations in research. Quantitative pharmacology approaches such as PBPK support optimized trial designs, safer dosing regimens, and ethical research frameworks. Emerging technologies further enhance insights drug exposures in mother-infant dyads
